Literature DB >> 28161838

Anticoagulant-related nephropathy: a case report and review of the literature of an increasingly recognized entity.

Rigas G Kalaitzidis1, Anila Duni2, Georgios Liapis3, Olga Balafa2, Sofia Xiromeriti2, Paulos Karolos Rapsomanikis2, Moses S Elisaf2,4.   

Abstract

Treatment with oral anticoagulants has been associated with worsening kidney function in patients with chronic kidney disease (CKD) as well as among patients without underlying CKD. Thus, anticoagulant-related nephropathy (ARN) is an increasingly recognized entity nowadays, mainly associated with warfarin anticoagulation. Recent evidence indicates that patients treated with the direct anticoagulants may also be at risk of ARN. However, the true incidence of anticoagulant-related nephropathy is difficult to determine. The typical histological lesion involves renal tubular occlusion by red blood cells (RBCs), tubular red blood cell casts on light microscopy and dysmorphic RBCs in the glomerulus on electron microscopy. In the absence of active glomerulonephritis or other inflammatory changes that could account for glomerular hemorrhage, the above findings confirm the diagnosis. Dabigatran etexilate was the first direct oral anticoagulant approved for stroke prevention in patients with non-valvular atrial fibrillation. In this article, we describe a rare case of dabigatran etexilate-induced nephropathy in a patient with preexisting IgA nephropathy and review the recent literature regarding this increasingly recognized entity.

Entities:  

Keywords:  Anticoagulant-related nephropathy; Dabigatran etexilate; IgA nephropathy; Oral anticoagulants; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28161838     DOI: 10.1007/s11255-017-1527-9

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  36 in total

1.  Risk of bleeding with dabigatran in atrial fibrillation.

Authors:  Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

2.  Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.

Authors:  Kyle Ware; Polina Brodsky; Anjali A Satoskar; Tibor Nadasdy; Gyongyi Nadasdy; Haifeng Wu; Brad H Rovin; Udayan Bhatt; Jon Von Visger; Lee A Hebert; Sergey V Brodsky
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

3.  Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.

Authors:  Joachim Stangier; Karin Rathgen; Hildegard Stähle; Dago Mazur
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

4.  Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.

Authors:  William E Dager; Robert C Gosselin; Steve Kitchen; Dennis Dwyre
Journal:  Ann Pharmacother       Date:  2012-12-11       Impact factor: 3.154

Review 5.  Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.

Authors:  C Chai-Adisaksopha; C Hillis; T Isayama; W Lim; A Iorio; M Crowther
Journal:  J Thromb Haemost       Date:  2015-10-05       Impact factor: 5.824

Review 6.  Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.

Authors:  Alexander G G Turpie; Reinhold Kreutz; Juan Llau; Bo Norrving; Sylvia Haas
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

7.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

8.  Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.

Authors:  Sergey V Brodsky; Tibor Nadasdy; Brad H Rovin; Anjali A Satoskar; Gyongyi M Nadasdy; Haifeng M Wu; Udayan Y Bhatt; Lee A Hebert
Journal:  Kidney Int       Date:  2011-03-09       Impact factor: 10.612

9.  Acute worsening of renal function during episodes of macroscopic hematuria in IgA nephropathy.

Authors:  M Praga; V Gutierrez-Millet; J J Navas; L M Ruilope; J M Morales; J M Alcazar; I Bello; J L Rodicio
Journal:  Kidney Int       Date:  1985-07       Impact factor: 10.612

10.  Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.

Authors:  Russell Berger; Steven D Salhanick; Maureen Chase; Michael Ganetsky
Journal:  Ann Emerg Med       Date:  2013-04       Impact factor: 5.721

View more
  10 in total

1.  Anticoagulating atrial fibrillation patients: is there a kidney-friendly choice?

Authors:  Chun-Yih Hsieh
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 2.  Anticoagulant-Related Nephropathy.

Authors:  Sergey Brodsky; John Eikelboom; Lee A Hebert
Journal:  J Am Soc Nephrol       Date:  2018-11-12       Impact factor: 10.121

3.  Dabigatran-induced anticoagulant-related nephropathy with undiagnosed IgA nephropathy in a patient with normal baseline renal function.

Authors:  Masaki Ikeda; Mari Tanaka; Saeko Shimoda; Hirona Saita; Seira Nishikawa; Hiroki Shimada; Keisuke Taniguchi; Koichiro Hagihara; Sachio Iwanari; Hiroya Takeoka
Journal:  CEN Case Rep       Date:  2019-07-25

4.  Dabigatran causing severe acute kidney injury in a patient with liver cirrhosis.

Authors:  Xin Li; Chi Yuen Cheung
Journal:  CEN Case Rep       Date:  2019-01-18

5.  Anticoagulant-related nephropathy: a pathological note.

Authors:  Vincenzo L'Imperio; Alessia Guarnieri; Federico Pieruzzi; Renato Alberto Sinico; Fabio Pagni
Journal:  J Thromb Thrombolysis       Date:  2018-08       Impact factor: 2.300

6.  IgA Nephropathy Is the Most Common Underlying Disease in Patients With Anticoagulant-Related Nephropathy.

Authors:  Hernando Trujillo; Justo Sandino; Teresa Cavero; Fernando Caravaca-Fontán; Eduardo Gutiérrez; Ángel M Sevillano; Amir Shabaka; Gema Fernández-Juárez; Pablo Rodríguez Doyágüez; Rocío Gimena Muñoz; Leonardo Calle García; Virginia Cabello; José Manuel Muñoz-Terol; Ana García Santiago; Oscar Toldos; Juan Antonio Moreno; Manuel Praga
Journal:  Kidney Int Rep       Date:  2022-01-19

7.  Acute kidney injury and undiagnosed immunoglobulin A nephropathy after dabigatran therapy.

Authors:  Laurie Jansky; Pallavi Mukkamala; Deborah Jebakumar; Arundhati Rao; Tove M Goldson; Samuel N Forjuoh
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-09

8.  Dabigatran-Induced Acute Interstitial Nephritis: An Important Complication of Newer Oral Anticoagulation Agents.

Authors:  Swapnil Patel; Mohammad A Hossain; Firas Ajam; Mayurkumar Patel; Mihir Nakrani; Jasmine Patel; Alsadiq Alhillan; Mohamed Hammoda; Anas Alrefaee; Michael Levitt; Arif Asif
Journal:  J Clin Med Res       Date:  2018-09-10

9.  Warfarin-Related Nephropathy Manifested as Diffuse Mesangial Proliferative Glomerulonephritis.

Authors:  Frederick Acquah; Nagapratap Ganta; Dina Alnabwani; Cecily Alaan; Priya Anantharaman; Pramil Cheriyath
Journal:  Cureus       Date:  2022-02-16

10.  Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.

Authors:  Géric Maura; Cécile Billionnet; Joël Coste; Alain Weill; Anke Neumann; Antoine Pariente
Journal:  Drug Saf       Date:  2018-09       Impact factor: 5.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.